It was the third trigger of the recession indicator in less than two weeks.Bondsread more
U.S. manufacturer growth slowed to the lowest in almost 10 years in August, the latest sign that the trade war may be exacerbating the economic slowdown.Marketsread more
"My sense was we've added accommodation, and it wasn't required in my view," George tells CNBC's Steve Liesman.Investingread more
Stocks traded higher on hopes the Fed chief will confirm expectations of easier monetary policy at a central banking summit this week.US Marketsread more
Apple plans to unveil three new iPhones in September, including two new "Pro" models and a successor to the iPhone XR, Bloomberg reported Thursday.Technologyread more
Former Prudent Bear Fund manager David Tice is urging investors to brace for a massive downturn.Trading Nationread more
Corporate profits posted modest growth in the second quarter as companies brace for slowing global growth.Retailread more
A Volkswagen spokesperson called the report that CEO Herbert Diess is interested in buying a stake in Tesla "completely unfounded."Technologyread more
A ruling against J&J could mean more big payouts in similar cases across the country.Health and Scienceread more
Pharmaceutical giant Merck said Tuesday that high consumer demand for its measles vaccines, amid the largest U.S. outbreak in decades, helped boost sales in its second quarter.
Sales of children's vaccines, which includes the New Jersey-based company's MMR vaccine, for measles, mumps and rubella, jumped 58% year over year to $675 million, Merck announced in its second-quarter earnings report Tuesday. Merck, which is the sole U.S. supplier of measles vaccines, said the strong growth was due in part to this year's measles outbreak, which was the largest in the U.S. since 1992.
"There was some buying to the private sector within the U.S. this quarter based on some of the measles outbreaks that you read in the news," Merck Chief Commercial Officer Frank Clyburn said in a post-earnings conference call with investors. "And we do believe that we'll continue to see growth for our pediatric vaccines going forward."
Shares of Merck were up more than 1% in midmorning trading after posting quarterly earnings and revenue that easily beat Wall Street's estimates. The company also narrowed its earnings and revenue forecast for the year due to its $1 billion acquisition of biotech firm Peloton Therapeutics, announced in May.
In May, Merck said it had increased production of the measles vaccine to meet an uptick in demand in the U.S. in the midst of the country's biggest outbreak in decades.
The Centers for Disease Control and Prevention has reported 1,164 individual cases of measles as of July 25. The CDC said the new cases represented a 1.4% increase in the number of cases from the previous week. Officials had officially declared measles eliminated in 2000, but warned that if cases continued to climb this year the U.S. may lose its "eliminated" status.
Before the creation of the measles vaccine in the 1960s, the disease infected an estimated 3 million to 4 million people, hospitalized 48,000 and claimed the lives of between 400 and 500 people annually.
Measles started to spread again in recent years as more parents refused to vaccinate their children, even though health officials stress immunizations are the best way to protect against the measles. The World Health Organization reported a 300% increase in measles cases in the first three months of this year compared with the same time last year.
— CNBC's Angelica LaVito contributed to this report.